CTLA4 and gastric cancer: Ipilimumab, as an anti-CTLA4 antibody, when combined with nivolumab, has been shown to be highly effective for dMMR gastric cancer (ORR 70, 95% confidence interval 35, 93 versus 57, 95% confidence interval 18, 90) [31].